Circle Pharma has appointed Anne Borgman as Chief Medical Officer.
Borgman brings extensive experience in clinical development strategy to the role, with a special focus on oncology. She previously held the role of CMO at Sutro Biopharma, where she led the company’s lead asset into ovarian cancer and infant leukaemia trials. She also previously served as Vice President and Therapeutic Area Lead, Oncology, Haematology and Transplant at Jazz Pharmaceuticals. During her time there, she oversaw the global development of a number of treatments, as well as emerging targets.
Borgman has also held leadership positions in oncology drug development at KaloBios Pharmaceuticals, Talon Therapeutics and Abbott Laboratories. She currently serves on the board of clinical-stage oncology companies NextCure, Curis and NiKang.
Borgman commented: “Circle Pharma’s MXMO platform is opening the door to a promising new class of targeted macrocycle therapies, with the potential to address some of the most challenging and impactful cancer targets, such as cyclins.”
David Earp, President and CEO of Circle, added: “Borgman joins Circle with an established track record of leading clinical development teams to successful oncology drug approvals in both the US and EU.”
Circle Pharma is a clinical-stage biopharmaceutical company focusing on targeted macrocycle therapeutics for cancer.